ibrutinib,venetoclax
abbvie,janssen,roche
['venetoclax', ' ibru', 'lymsm']
congress | #ash22
jorge j. castillo, shares insights into ibrutinib and venetoclax in previously untreated #wm. the combination was associated with a major response rate of 93%, and a vgpr rate of 40%. however, the study finished early due to safety concerns.
#lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm